Immunic, Inc.

Biotechnology • Healthcare • New York, NY, United States • IMUX (NMS)

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

332 255 9818 1200 Avenue of the Americas, New York, NY 10036, United States

Stock Performance (90 Days)

Data through Dec 29, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

PR Newswire • Nov 13

Positive Signs As Multiple Insiders Buy Immunic Stock - Yahoo Finance

Yahoo Finance • Oct 2

B.Riley lowers Immunic stock price target to $4 as catalyst-rich period approaches - Investing.com

Investing.com • Sep 2

Immunic (IMUX) Has a New Rating from Chardan Capital - The Globe and Mail

The Globe and Mail • Jan 2

Immunic's MS drug shows 'modest' brain volume impact, stock tumbles - FirstWord Pharma

FirstWord Pharma • Apr 30

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has IMMUNIC, INC. had layoffs?

No layoff events have been recorded for IMMUNIC, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does IMMUNIC, INC. have?

IMMUNIC, INC. has approximately 90 employees.

What industry is IMMUNIC, INC. in?

IMMUNIC, INC. operates in the Biotechnology industry, within the Healthcare sector.

Is IMMUNIC, INC. a publicly traded company?

Yes, IMMUNIC, INC. is publicly traded under the ticker symbol IMUX on the NMS. The company has a market capitalization of approximately $0.06 billion.

Where is IMMUNIC, INC. headquartered?

IMMUNIC, INC. is headquartered in New York, NY, United States at 1200 Avenue of the Americas, New York, NY 10036, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.